Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
71,665.00
(
-1.93%
)
News Focus
News Focus
Post# of 447267
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Number sleven

Send PM Follow Ignore
Followers 35
Posts 8849
Boards Moderated 1
Alias Born 04/04/2020

Number sleven

Re: DAR53 post# 436993

Friday, 06/27/2025 7:34:41 AM

Friday, June 27, 2025 7:34:41 AM

Post# of 447267
DAR53, Patents aren't the issue. It's the indication granted by FDA. The NDA is how the generic companies weasel into the market with an ANDA. Read the post by Tatsumaki. According to him we don't need to apply for the SHTG indication for the new formulation. Assuming we intend to get approval for that product.
Sleven,
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News